Contrarian Take: This High-Yield Dividend Stock Is a Buy in May Despite Falling to an 11-Year Low

Clorox cut fiscal 2026 organic sales guidance to a 9% decline from prior guidance of a 5% to 9% decline, and management said $100-per-barrel oil would hit quarterly gross profit by $20 million to $25 million, or 130 bps of gross margin. The company is still seeing strength in cleaning and international segments, but litter and food are weak and competitive discounting is pressuring sales. Clorox completed its $2.25 billion cash acquisition of GOJO, adding about $200 million in quarterly revenue and roughly 10% to total company sales, while the stock trades at 13.7x fiscal 2027 earnings and yields 5.7%.

Analysis

The near-term market setup is less about the size of the miss and more about credibility compression. When a consumer staples name keeps resetting guidance, the multiple usually de-rates before fundamentals stabilize; the stock can remain cheap for longer than expected because dividend support does not offset repeated forecast cuts. The second-order effect is that any further “portfolio simplification” can help margins mechanically, but it also signals management is admitting the category mix has been suboptimal, which keeps sentiment anchored.

GOJO is strategically sensible because it pushes CLX toward a higher-intent hygiene franchise rather than low-differentiation adjacency bets. The hidden risk is integration: a cash deal with meaningful revenue contribution raises execution burden at exactly the moment the core business is under pressure. If synergies are slower than expected, the market may treat the acquisition as a distraction rather than a fix, and that can keep the stock trapped in value purgatory for several quarters.

The most important missing piece in consensus is that the yield may be a trap if the earnings base is still being revised downward. A 5-6% dividend can attract passive buyers, but if organic sales stay weak and input costs stay volatile, management may have to choose between defending the payout and preserving balance-sheet flexibility for restructuring. That makes the next 1-2 earnings prints the key catalyst window: stabilization would likely rerate the shares modestly, but another cut could force a fresh leg lower despite the headline cheapness.

Relative winners are private-label and value-positioned competitors that can keep taking share in price-sensitive categories without needing to sacrifice margin as aggressively. The broader trade implication is that this is not a clean long-staples signal; it is a selective short on execution risk and a selective long on better-managed category leaders with stronger pricing power.

Key Decisions for Investors

• Avoid initiating a new long in CLX ahead of the next 1-2 quarterly prints; wait for evidence that guidance is inflecting upward rather than just less-bad, because the stock can re-rate down another 10-15% on one more reset.
• Use CLX as a candidate short against a higher-quality consumer staples long: long PG / short CLX, 3-6 month horizon, to isolate execution dispersion and reduce market beta if consumer demand stays soft.
• For income-focused exposure, prefer buying CLX only via cash-secured puts or downside-defined structures (e.g., 3-6 month put spreads) rather than outright stock; the implied downside from another guidance cut is larger than the near-term upside from yield support.
• Monitor GOJO integration metrics over the next two earnings calls; if revenue stays near the stated run-rate but margins fail to expand, treat the acquisition as neutral-to-negative and fade any relief rally.
• If CLX breaks to new lows on another estimate revision, consider a tactical long only after capitulation volume, as a mean-reversion trade with strict stop-losses; the dividend can provide floor support, but only after credibility is rebuilt.